Bolt Biotherapeutics, Inc.
BOLT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2,169 | $1,804 | $1,222 | $0 |
| % Growth | 20.2% | 47.6% | – | – |
| Cost of Goods Sold | $290 | $0 | $0 | $426 |
| Gross Profit | $1,879 | $1,804 | $1,222 | -$426 |
| % Margin | 86.6% | 100% | 100% | – |
| R&D Expenses | $6,245 | $7,498 | $9,512 | $11,296 |
| G&A Expenses | $0 | $3,516 | $3,825 | $0 |
| SG&A Expenses | $3,337 | $3,516 | $3,825 | $3,947 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,582 | $11,014 | $13,337 | $15,243 |
| Operating Income | -$7,703 | -$9,210 | -$12,115 | -$15,669 |
| % Margin | -355.1% | -510.5% | -991.4% | – |
| Other Income/Exp. Net | $559 | $649 | $1,075 | -$267 |
| Pre-Tax Income | -$7,144 | -$8,561 | -$11,040 | -$15,936 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,144 | -$8,561 | -$11,040 | -$15,936 |
| % Margin | -329.4% | -474.6% | -903.4% | – |
| EPS | -3.722 | -4.46 | -0.29 | -0.42 |
| % Growth | 16.5% | -1,437.9% | 31% | – |
| EPS Diluted | -3.722 | -4.46 | -0.29 | -0.42 |
| Weighted Avg Shares Out | 1,919 | 1,918 | 38,340 | 38,285 |
| Weighted Avg Shares Out Dil | 1,919 | 1,918 | 38,340 | 38,285 |
| Supplemental Information | – | – | – | – |
| Interest Income | $477 | $599 | $1,053 | $980 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $290 | $347 | $399 | $426 |
| EBITDA | -$6,854 | -$8,863 | -$11,716 | -$15,510 |
| % Margin | -316% | -491.3% | -958.8% | – |